Project Grant R01CA287476
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$549K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This federal Project Grant award of $216,972 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to understand and target vulnerabilities governing the G1/S transition and replication stress in small cell lung cancer (SCLC). The key objectives are to: 1) determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA levels and R-loops, and develop therapeutic approaches targeting...
This $3,787,956.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The research aims to: 1) understand how the SLFN11 gene impacts chemotherapy response in SCLC subtypes, 2) study how replication stress response pathways and modulators regulate chemosensitivity, and 3) develop strategies to target replication...
The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $158,365 to the University of North Carolina at Chapel Hill to study the effects of NRF2 signaling on the development of lung squamous cell carcinoma (LUSC). The research aims to understand how NRF2 activation impacts LUSC initiation, progression, and the tumor microenvironment using a novel genetically-engineered mouse model. The University of Washington will perform multi-omics...
This Project Grant award of $230,010 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to unravel the cellular and molecular drivers behind the aggressive metastasis of small cell lung cancer (SCLC). The award was granted to the University of Chicago and will run from March 1, 2025 to February 28, 2027. The research integrates human pluripotent stem cell-derived SCLC models, clinical samples, and patient-derived...
The National Cancer Institute (NCI) awarded a $652,799 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Fred Hutchinson Cancer Center in Seattle, WA. The grant will fund a 5-year research project to investigate the mechanistic details of "MAPK-driven kinetochore stress" (MASKS) in cancer, particularly glioblastoma. The research aims to reveal how oncogenic signaling via the RAS-RAF-MEK-ERK pathway disrupts kinetochore function, leading to chromosome...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $169,884 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to research the molecular mechanisms regulating the POU2F3 oncoprotein and its potential as a therapeutic target for small cell lung cancer (SCLC). The key objectives are to: 1) Explore how the E3 ubiquitin ligase APC/CDC20 regulates POU2F3 ubiquitination and stability in SCLC-P, a POU2F3-driven subtype of SCLC; and 2) Assess...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $191,675.00 to The University of Texas Southwestern Medical Center to conduct research on innovative therapeutic strategies for small cell lung cancer (SCLC). The research aims to investigate the role of Jumonji demethylases as potential druggable targets in SCLC, including evaluating the impact of Jumonji inhibitors on SCLC growth and therapeutic resistance. The project will...
This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...
The National Cancer Institute (NCI) awarded a $512,974 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research institution located in New York City. The grant, effective August 13, 2024 through July 31, 2029, will fund research to develop advanced predictive models for non-small cell lung cancer (NSCLC) outcomes using a combination of real-world data sources, including tumor genomic...